Topics

Videos

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations. 

Trade & Channel Strategies 2024: The Significance of Return on Invested Capital for Pharma Companies

Podcasts

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report. 

The Path Forward for Infused Biosimilars in the US

Articles

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia. 

Novo Nordisk Financially Commits $1.2 Billion Toward New Danish Production Plant

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

Trade & Channel Strategies 2024: Navigating Pharma and Its Distribution Models

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year. 

Trade & Channel Strategies 2024: Access and Channel 2024 Year-in-Review and Preview of 2025

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Examining Launch, Post-Launch Price Developments in the United States and Europe

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities. 

Amgen, Lilly Unveil Major Expansion Projects

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

Toripalimab Launches in India

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

PTC Therapeutics, Novartis Sign License and Collab Deal for Huntington’s Disease Program

Why well-organized documentation is critical at every stage of the process.

Business and Finance